Table of contents

• Trial overview
• Who can join the study
• What the study measures
• Study parts and treatment approach
• Trial phase and status
• Key terms explained

Trial overview

This study is a Phase 1/2 trial of GSK5460025A in people with dMMR/MSI-H solid tumors, including colorectal cancer.^[1] The trial is designed to look first at safety and dose, then at early signs that the treatment may help shrink tumors.^[1]

The study is interventional, which means participants receive a study treatment rather than only being observed.^[1] The trial status is Authorised, and the planned enrollment is 47 participants.^[1]

Who can join the study

The main target population is people with dMMR/MSI-H solid tumors.^[1] The trial title also shows a focus on solid tumors, and the brief summary names colorectal cancer for one part of the study and endometrial cancer for another part.^[1]

Based on the trial data, this study is aimed at people whose cancer fits these tumor features and cancer types, rather than a general cancer population.^[1]

What the study measures

The first part of the study checks dose limiting toxicities, which are side effects that may stop the dose from being increased.^[1] It also measures treatment-emergent serious adverse events and other treatment-emergent adverse events, which are health problems that appear after treatment starts.^[1]

Other safety measures include how long these side effects last and whether dose changes are needed because of side effects.^[1] These outcomes help researchers decide the recommended dose for expansion and/or the maximum tolerated dose.^[1]

The second part measures Objective Response Rate, or ORR, which is the percentage of participants with a confirmed complete response or partial response.^[1] In simple terms, this shows how many tumors fully disappear or shrink enough to count as a response under the study rules.^[1]

Study parts and treatment approach

Part 1 studies GSK5460025A as monotherapy, meaning it is given alone.^[1] In this part, the main goal is to find out if the treatment is safe enough and what dose should be used for later study.^[1]

Part 2 looks at early anti-tumor activity in colorectal cancer and, separately, endometrial cancer.^[1] The trial title also says GSK5460025A may be studied alone or in combination with other anti-cancer agents, so the research plan includes both single-drug and combination approaches.^[1]

Trial phase and status

This is a Phase 1/2 study, so it combines early safety testing with early effectiveness testing.^[1] Phase 1 helps researchers understand safety, dose, and tolerability, while Phase 2 looks for signs that the treatment is working against cancer.^[1]

The status is listed as Authorised, which means the study has approval to proceed according to the source data.^[1]

Key terms explained

dMMR means deficient mismatch repair, a problem in the cell’s DNA repair system.^[1] MSI-H means microsatellite instability-high, which is another way of describing a tumor with many DNA changes from poor repair.^[1]

RECIST 1.1 is a standard set of rules used to measure tumor response in cancer trials.^[1] A complete response means no signs of the tumor are found, and a partial response means the tumor has shrunk enough to count as a response under the study rules.^[1]

Serious adverse events are harmful medical events that are severe enough to matter a lot in a study, while other adverse events are side effects of any level of severity.^[1] Tolerability means how well participants can stay on treatment without major problems.^[1]

Table of Contents

• Trial overview
• Who can participate
• What is being measured
• Study design and phase
• What the study may mean for patients

Trial overview

The clinical trial with ID 2025-524719-35-00 is a study of MB-001 in adults with moderate to severe ulcerative colitis.^[1] It is an interventional study, which means researchers give a treatment and then measure the results.^[1] The study is authorised and plans to enroll 100 participants.^[1]

Who can participate

The trial is for adults with moderately to severely active ulcerative colitis.^[1] The source data do not list more detailed entry rules, so the available information only confirms the condition, age group, and disease activity level.^[1]

What is being measured

The main safety measures include the number of adverse events, treatment-emergent adverse events, serious adverse events, adverse events of special interest, and treatment stopping because of treatment-emergent adverse events through Week 12.^[1] The study also checks changes in laboratory tests, physical examination findings, and vital signs through Week 12.^[1]

The main efficacy measure is the proportion of participants who reach clinical remission at Week 12.^[1] In this study, clinical remission is defined by a modified Mayo Score of 2 or less, a Mayo endoscopic subscore of 1 or less, rectal bleeding subscore of 0, and stool frequency subscore of 1 or less.^[1] These scores are used to show how active ulcerative colitis is, with lower scores meaning less disease activity.^[1]

Study design and phase

This is a Phase 1 trial, which is an early stage of testing.^[1] Phase 1 studies usually focus on safety and tolerability, and this trial follows that pattern by also looking for early signs of efficacy, or benefit.^[1] The study compares MB-001 with a placebo, which is a look-alike treatment that has no active ingredient.^[1]

MB-001 is given orally in this trial, meaning it is taken by mouth.^[1] The placebo uses the same formulation excipients as the MB-001 product except for the active ingredient.^[1]

What the study may mean for patients

This study is designed to learn whether MB-001 can be studied safely in people with active ulcerative colitis and whether it may help reduce disease signs.^[1] The key patient-focused outcome is whether more participants can reach remission by Week 12, while also watching for unwanted medical problems during treatment.^[1] Because the trial is early stage, it is mainly about learning and comparison rather than proving long-term benefit.^[1]

Table of contents

• Trial overview
• Who can participate
• Study design and phase
• What the study measures
• Trial status and size
• Patient glossary of key terms

Trial overview

The available study for 5,7-DICHLORO-2-((ETHYLAMINO)METHYL)-8-HYDROXY-3-METHYLQUINAZOLIN-4(3H)-ONE METHANESULFONATE is an open-label extension study called “Open-Label Extension Study to Provide Access to ATH434 in Patients with Multiple System Atrophy.”^[1] It is studying people with multiple system atrophy (MSA).^[1]

The brief summary says the study is designed to assess the long-term safety and tolerability of ATH434 in participants with MSA who are receiving open-label treatment.^[1]

Who can participate

The source data show that the target population is participants with multiple system atrophy.^[1] The study is an extension study, so it is for people already receiving open-label treatment in this setting.^[1]

The trial record does not provide more detailed entry rules such as age limits, disease stage, or other eligibility requirements.^[1]

Study design and phase

This is an interventional study, which means participants receive a study treatment and researchers observe the results.^[1] The study is listed as Phase 2.^[1]

It is also open-label, meaning there is no blinding in the source data and participants receive the study drug with researchers aware of the treatment being given.^[1] The study is an extension study, which means it continues follow-up after earlier research so that longer-term data can be collected.^[1]

The intervention listed in the trial record is ATH434-DP2, given by oral use at 150 mg/g milligram(s)/gram.^[1]

What the study measures

The primary outcome is long-term safety and tolerability.^[1] Safety means whether harmful medical problems happen, and tolerability means whether people can continue treatment without too much trouble.

Researchers are measuring the incidence and severity of adverse events and serious adverse events.^[1] An adverse event is any unwanted health problem during a study, while a serious adverse event is a more severe problem.^[1]

The study also checks changes in laboratory and vital sign parameters, including orthostatic measures.^[1] Orthostatic measures are checks related to what happens when a person stands up, such as changes in blood pressure.^[1]

Other measured outcomes include exposure to ATH434, treatment discontinuations due to adverse events, and deaths.^[1] These measures help researchers understand how the treatment is used over time and whether people stop it because of side effects.^[1]

Trial status and size

The study status is Authorised.^[1] The enrollment is 7 participants, so this is a small study.^[1]

Because the available trial data describe one authorised Phase 2 study, the article focuses on this single clinical trial rather than a larger trial program.^[1]

Patient glossary of key terms

• Authorised: The study has official approval to run, based on the source record.^[1]
• Enrollment: The number of participants planned or entered in the study.^[1]
• Interventional study: A study where a treatment is given to participants and then studied.^[1]
• Open-label extension study: A follow-up study in which everyone knows the treatment and the study continues to collect data over time.^[1]
• Laboratory parameters: Test results used to monitor health and safety.^[1]
• Vital signs: Basic body measurements such as pulse and blood pressure.^[1]

Table of contents

• Trial overview
• Who can join the study
• Treatment and comparison
• Outcomes being measured
• Trial status and size
• What this means for patients

Trial overview

The available study is an interventional clinical trial, which means researchers give a treatment and then measure the results.^[1] It is testing LEPIDOGLYPHUS DESTRUCTOR, POLYMERISED EXTRACT for people with allergy related to dust mite and Lepidoglyphus destructor.^[1]

The trial is designed to assess both efficacy and safety, with efficacy meaning how well the treatment works in real participants.^[1] The study is in Phase 3, which is a later stage of testing in a larger group of people.^[1]

Who can join the study

The study includes participants aged 12 to 65 years.^[1] It focuses on people with moderate-to-severe persistent allergic rhinitis or rhinoconjunctivitis.^[1]

Some participants may also have mild-to-moderate controlled allergic asthma.^[1] In simple terms, this means the asthma is present but is stable and not severe at the time of the study.^[1]

Treatment and comparison

The trial compares the active study product with a placebo, which looks the same but does not contain active ingredients.^[1] The active product is given as a suspension for injection under the skin.^[1]

This design helps researchers see whether any improvement is due to the study treatment and not to chance or expectation alone.^[1]

Outcomes being measured

The main outcome is the Rhinoconjunctivitis Combined Symptom and Medication Score, also called RCSMS.^[1] This score combines two important parts: how bad the allergy symptoms are and how much allergy medicine the participant needs.^[1]

The score is measured over 4 weeks after one year of treatment, and it is recorded in the participant diary.^[1] This helps researchers understand the treatment effect over time in daily life.^[1]

Trial status and size

The study status is Authorised.^[1] The planned enrollment is 120 participants, which means the trial is set up to include 120 people.^[1]

Because the trial is relatively small compared with many late-stage studies, each participant’s data will be important for understanding the results.^[1]

What this means for patients

For patients, this study is looking at whether LEPIDOGLYPHUS DESTRUCTOR, POLYMERISED EXTRACT can help reduce allergy symptoms in people with dust mite and Lepidoglyphus destructor allergy.^[1] The trial is especially relevant for people who have ongoing nose and eye allergy symptoms, with or without stable asthma.^[1]

The most important question in the study is whether the treatment can improve daily symptoms and lower the need for allergy medicine over time.^[1]

Table of Contents

• Trial overview
• Study design and treatment groups
• Who can participate
• What researchers are measuring
• Trial status and size

Trial overview

This clinical trial is studying AUR200 in people with generalized myasthenia gravis, a condition that causes muscle weakness in many parts of the body.^[1] The study is designed to look at both safety and early signs that the treatment may help with daily life in this disease.^[1]

Study design and treatment groups

The trial is described as a double-blind, randomized, placebo-controlled study.^[1] This means people are assigned by chance to a study group, and neither the participant nor the study team knows who receives AUR200 or placebo during the study.^[1]

The intervention is given by subcutaneous injection, which means an injection under the skin.^[1] The source data list AUR200 and a placebo-like comparison treatment as the study interventions.^[1]

Who can participate

The trial is for patients with generalized myasthenia gravis.^[1] The source data do not provide more detailed entry rules, so exact eligibility depends on the study screening process.^[1]

What researchers are measuring

In Phase 1, the main outcome is the incidence of treatment-emergent adverse events, which means how often new health problems or worsening health problems happen after treatment starts.^[1] This part of the study is focused on safety and tolerability.^[1]

The brief summary also describes a Phase 2 part that looks at efficacy, which means whether the treatment works.^[1] The main Phase 2 outcome is the change from baseline in MG-ADL total score, a measure of how much myasthenia gravis affects daily activities such as speaking, chewing, and walking.^[1]

Trial status and size

The study status is Authorised.^[1] The planned enrollment is 51 participants, which means the trial is designed to include 51 people in total.^[1]

Because this is a small early-stage study, the main goal is to learn whether AUR200 can be studied safely in this patient group and whether there are early signs of benefit.^[1]

Table of Contents

• Trial overview
• Who is being studied
• Treatments and comparators
• Phase and study design
• Endpoints being measured
• What the study may mean for patients

Trial overview

The main study in the data is titled FORAGER-2 and is listed as an authorised Phase 3 interventional trial.^[1] It is studying people with cancer in the urinary tract, including bladder cancer that is advanced or has spread.^[1]

The trial includes “(S)-4-(4-(3-CHLORO-4-(1-(5-FLUOROPYRIDIN-2-YL)-2-HYDROXYETHOXY)PYRAZOLO[1,5-A]PYRIDIN-6-YL)-5-METHYL-1H-1,2,3-TRIAZOL-1-YL)PIPERIDINE-1-CARBONITRILE” as part of the study treatment plan.^[1] The study purpose is to see whether the treatment is safe and whether it can help people with this cancer.^[1]

Who is being studied

The trial targets participants with carcinoma, transitional cell, urinary bladder neoplasms, and neoplasm metastasis.^[1] In simple terms, this means the study is focused on cancer that starts in the lining of the urinary tract and may have spread to other parts of the body.^[1]

The brief summary says the study is for people with bladder cancer that is advanced or has spread.^[1] This is important because the trial is not looking at early cancer only; it is focused on more serious disease.^[1]

Treatments and comparators

The study compares vepugratinib with placebo.^[1] A placebo is a look-alike treatment used for comparison, so researchers can see whether the study medicine makes a difference.^[1]

The data also shows that vepugratinib or placebo is given together with enfortumab vedotin and pembrolizumab.^[1] The trial therefore studies a combination approach rather than a single medicine alone.^[1]

The intervention list includes oral use for LOXO-435 and the listed substance, and intravenous use for pembrolizumab and enfortumab vedotin.^[1] The source data does not provide more detail about dosing beyond what is listed in the intervention names.^[1]

Phase and study design

This is an interventional study, which means the researchers are assigning treatments and then measuring what happens.^[1] The study is in Phase 3, a later stage of clinical research that usually involves larger groups and direct comparison of treatments.^[1]

The enrollment is listed as 503 participants.^[1] The brief summary also says participation could last up to about 6 years, showing that the study includes long-term follow-up.^[1]

Endpoints being measured

The main outcomes include safety and tolerability of vepugratinib in combination with enfortumab vedotin and pembrolizumab.^[1] Safety and tolerability mean how safe the treatment appears and how well people can handle it during the study.^[1]

Another key outcome is overall response rate (ORR).^[1] This measures how many participants have their cancer shrink or disappear during treatment.^[1]

The study also measures progression-free survival (PFS) by blinded independent central review (BICR).^[1] PFS means the time before the cancer gets worse, and BICR means scan results are reviewed by experts who do not know which treatment the person received.^[1]

What the study may mean for patients

This trial is designed to learn whether the study treatment can help people with advanced urinary tract cancer while keeping safety under close review.^[1] Because it is a Phase 3 study, the results may help show whether the treatment has enough benefit to support future use in this cancer setting.^[1]

For patients, the most important parts of the study are the cancer type being targeted, the comparison against placebo, and the long follow-up period.^[1] These details show that the researchers are looking not only at short-term tumor response, but also at how the treatment performs over time.^[1]

Table of Contents

• Trial overview
• Study design and treatment groups
• Who can participate
• What is being measured
• Trial status and size

Trial overview

One clinical trial is listed for “(2S)-2-[[2-[[(2S)-5-AMINO-2-[[(2S)-2-AMINOPROPANOYL]AMINO]-5-OXOPENTANOYL]AMINO]ACETYL]AMINO]-3-METHYLBUTANOIC ACID”. The study is an interventional trial, which means researchers give a treatment and then measure the results.^[1]

The trial is focused on people with coronary artery disease who are having on-pump coronary artery bypass grafting surgery.^[1]

Study design and treatment groups

This study is a Phase 3 trial, which is a later-stage study in a larger group of patients.^[1]

It is described as randomized, double-blind, and placebo-controlled.^[1]

Randomized means patients are assigned by chance to a study group. Double-blind means neither the patient nor the study team knows which treatment is given. Placebo-controlled means one group receives a comparison treatment that does not contain the active study drug.^[1]

• One group receives EA-230 given by intravenous administration, which means through a vein.^[1]
• The other group receives NaCl 29 mg/ml in water for injection, which is the placebo used for comparison.^[1]

Who can participate

The source data says the trial is for people with coronary artery disease who are undergoing on-pump coronary artery bypass grafting surgery.^[1]

No more detailed inclusion or exclusion rules are provided in the trial data, so the full eligibility list is not available here.^[1]

What is being measured

The main goal of the trial is to assess the effect of the study treatment on postoperative hospital length of stay, which means how long a patient stays in the hospital after surgery.^[1]

The primary outcome is the median postoperative duration from the first incision until the patient is eligible to be discharged from the hospital.^[1]

Median means the middle value in a group of results. The study compares this outcome between the treatment groups using the trial’s discharge criteria.^[1]

Trial status and size

The trial status is Authorised.^[1]

The planned enrollment is 300 people.^[1]

Table of Contents

• Trial overview
• Who is being studied
• Study phase and design
• What researchers measure
• Trial status and size

Trial overview

The available trial is a first-in-human study of ADENO-ASSOCIATED VIRUS SEROTYPE 9 CONTAINING THE HUMAN GCG GENE in adults with inadequately controlled type 2 diabetes.^[1] It is designed to evaluate safety and tolerability, which means the researchers want to see how the study treatment is handled by the body and whether it causes important problems.^[1]

Who is being studied

The target population is adults with type 2 diabetes whose condition is not well controlled.^[1] The source data does not give more details about age limits, lab cutoffs, or other eligibility rules, so only this group can be confirmed from the trial record.^[1]

Study phase and design

This study is listed as a Phase 1/2 trial.^[1] Early-phase trials like this usually focus first on safety, and they may also begin to look for early signs that the treatment has a useful effect.^[1]

The trial is interventional, which means participants receive the study treatment rather than only being observed.^[1] The intervention is listed as RJVA-001 given by endoscopic ultrasound-guided delivery, a procedure that uses an endoscope and ultrasound imaging to guide treatment placement inside the body.^[1]

What researchers measure

The main outcome is the incidence and severity of adverse events, plus any dose-relationship and changes in laboratory evaluations.^[1] Adverse events are unwanted medical problems that happen during a study, and laboratory evaluations are tests such as blood work that help researchers watch for changes in health.^[1]

These outcomes are important because they help show whether the treatment appears safe enough for further study and whether different treatment amounts may affect the body differently.^[1]

Trial status and size

The trial status is Authorised, which means it has been approved to begin according to the source record.^[1] The planned enrollment is 50 participants, making this a small early study.^[1]

Table of Contents

• Trial overview
• Who is being studied
• Treatments being compared
• Study endpoints
• Trial status and size

Trial overview

The main trial in the data is NCT07213804, a Phase 3 interventional study of LY4170156, also called Sofetabart Mipitecan, in ovarian cancer and related cancers.^[1]

The study is designed in two parts: Part A for platinum-resistant ovarian cancer and Part B for platinum-sensitive ovarian cancer.^[1]

Who is being studied

The trial includes people with ovarian neoplasms, fallopian tube neoplasms, peritoneal neoplasms, and neoplasm metastasis.^[1]

These names mean the cancer starts in the ovary, fallopian tube, or peritoneum, and in some cases has spread to another part of the body.^[1]

Part A focuses on people whose cancer is platinum-resistant, which means the cancer did not respond well to platinum treatment or returned soon after it.^[1]

Part B focuses on people whose cancer is platinum-sensitive, which means the cancer still responds to platinum-based treatment.^[1]

Treatments being compared

In Part A, the study compares Sofetabart Mipitecan (LY4170156) with the control arm, which is the investigator’s choice of chemotherapy or mirvetuximab soravtansine (MIRV).^[1]

In Part B, the study compares Sofetabart Mipitecan plus bevacizumab with the control arm of investigator’s choice platinum-based doublet chemotherapy plus bevacizumab.^[1]

These control arms show what standard treatment options the study is using for comparison, so researchers can see whether the LY4170156-based approach works better.^[1]

Study endpoints

The main outcome in Part A is progression-free survival (PFS) measured by RECIST v1.1 and assessed by the investigator.^[1]

The main outcome in Part B is progression-free survival measured by RECIST v1.1 and reviewed by blinded, independent, central review (BICR).^[1]

Progression-free survival means the time during and after treatment when the cancer does not get worse.^[1]

RECIST v1.1 is a standard method for measuring whether tumors grow, shrink, or stay the same.^[1]

BICR means independent experts review the results without knowing which treatment a person received, which helps make the comparison fair.^[1]

Trial status and size

The study status is Authorised, which means it has been approved to move forward.^[1]

The planned enrollment is 1,125 participants, showing that this is a large study.^[1]

The trial is interventional, meaning the researchers assign treatments and then measure the results.^[1]

Table of Contents

• Trial overview
• Who was studied
• Trial goals and study phase
• Main endpoints
• Trial status and enrollment

Trial overview

This clinical trial studied ALLOGENEIC ADIPOCYTE-DERIVED MESENCHYMAL STROMAL CELLS TRANSDUCED WITH A LENTIVIRAL PROVIRUS VECTOR CONTAINING THE HUMAN CXCR4 AND IL-10 GENES for acute graft-versus-host disease (acute GVHD).^[1]

The study was designed as an interventional trial, which means the researchers planned to give a study treatment and watch what happened.^[1]

Who was studied

The trial focused on patients who had developed acute GVHD that was refractory, meaning it did not respond well to treatment.^[1]

More specifically, it included patients whose disease was refractory to corticosteroids and ruxolitinib, or patients who were not eligible to receive ruxolitinib.^[1]

In simple terms, this was a group of people with difficult-to-treat disease and limited treatment options.^[1]

Trial goals and study phase

This was a Phase 1 trial.^[1]

Phase 1 studies usually look first at safety and tolerability, which means whether the treatment can be given without causing too much harm and whether patients can handle it reasonably well.^[1]

The brief summary said the study aimed to analyze the safety and tolerability of the administration of the study treatment in patients with acute GVHD who had few remaining options.^[1]

Main endpoints

The primary outcome was safety, measured by serious adverse reactions after sequential infusions of the study drug during the full follow-up period.^[1]

The trial also looked for serious unexpected adverse reactions at the time of infusion or during follow-up.^[1]

These endpoints show that the study was mainly checking for harmful reactions and how patients responded over time.^[1]

Trial status and enrollment

The trial status was Withdrawn, which means it did not continue as planned.^[1]

The planned enrollment was 15 patients.^[1]

The trial title described the treatment as a new generation of mesenchymal stromal cells that ectopically express CXCR4 and IL-10, and the intervention was given by intravenous infusion.^[1]

Table of contents

• Trial overview
• Who is being studied
• What is being tested
• Study phase and design
• What outcomes are measured
• How to read the study results

Trial overview

The available trial for TRIACYLGLYCEROL LIPASE is a Phase 2 interventional study in adults with exocrine pancreatic insufficiency (EPI).^[1] It is authorised and plans to enroll 44 participants.^[1]

The study title says it will evaluate safety and explore efficacy of a new lipase called NHS7108 compared with pancrelipase.^[1] “Efficacy” means how well a treatment works.^[1]

Who is being studied

This trial is for adult participants with exocrine pancreatic insufficiency.^[1] EPI is the condition being studied, and the trial data do not give more detailed eligibility rules.^[1]

People in this study are being followed because they need support with digestion and nutrient absorption.^[1] The study is not described as a pediatric trial, so the listed population is adults only.^[1]

What is being tested

The study compares NHS7108 capsules with Zenpep delayed-release capsules, which are listed as pancrelipase in the trial record.^[1] Both are given by mouth.^[1]

The brief summary says different doses of NHS7108 are given daily for 14 days in participants with EPI.^[1] This means the researchers are looking at short-term treatment effects over two weeks.^[1]

Study phase and design

This is an interventional trial, which means participants receive a study treatment and researchers observe the effects.^[1] It is a Phase 2 study, so the main focus is safety with early signs of benefit.^[1]

Phase 2 studies often help researchers decide whether a treatment should be studied further in larger groups.^[1] In this trial, the study is also meant to compare the new treatment with an existing one used for the same condition.^[1]

What outcomes are measured

The main safety outcome is the number of participants who report one or more adverse events.^[1] An adverse event is any unwanted health problem that happens during the study.^[1]

Researchers also track changes from baseline in safety parameters after 14 days of NHS7108 treatment.^[1] These safety checks include clinical laboratory tests, vital signs, 12-lead electrocardiogram (ECG), and physical examination.^[1]

Another key measure is the change from baseline in coefficient of nitrogen absorption (CNA) after 14 days.^[1] CNA is used here as a way to assess how well the body absorbs nitrogen, which helps show protein absorption.^[1]

How to read the study results

Because this is a small Phase 2 study, the results will mainly help show whether the treatment is safe enough and whether it may be worth studying more.^[1] The study does not yet provide final proof that the treatment works better than the comparison treatment.^[1]

For patients, the most important points are the condition studied, the adult population, the short 14-day treatment period, and the safety-focused outcomes.^[1] These details show that the trial is an early step in learning more about TRIACYLGLYCEROL LIPASE-related treatment research.^[1]

Table of Contents

• Trial overview
• Who is being studied
• What the study measures
• Trial design and phase
• Why this trial matters

Trial overview

The available study of VTX-002 is titled “A Phase 1/2 Study of the Safety and Tolerability of ICM VTx-002 in participants with ALS.”^[1] It is an interventional trial, which means researchers give the study treatment and then watch what happens.^[1] The trial is listed as Authorised and plans to enroll 12 participants.^[1]

Who is being studied

This trial is for people with amyotrophic lateral sclerosis (ALS).^[1] ALS is the condition named in the trial record, and no other target population is listed.^[1] The source data do not provide more detailed inclusion or exclusion rules, so the exact entry criteria are not known from the trial summary alone.^[1]

What the study measures

The main goal is to assess the safety and tolerability of increasing doses of a single administration of VTX-002.^[1] Safety means whether unwanted medical problems happen, and tolerability means how well participants can handle the treatment.^[1]

The primary outcome looks at the nature, number, severity, relatedness, seriousness, and outcome of treatment-emergent adverse events (new health problems that start after treatment begins).^[1] The study also checks laboratory values, MRI findings, the Treatment-induced Peripheral Neuropathy Assessment Scale (TNAS), cellular responses to both the vector and the transgene encoded protein, and the Columbia Suicide Severity Rating Scale (C-SSRS).^[1]

These measures help researchers see whether the treatment affects the body in ways that may matter for future research in ALS.^[1] They also give a fuller safety picture than side effects alone because they include scans, blood or other test results, nerve symptom checks, and mental health screening.^[1]

Trial design and phase

This study is in Phase 1/2, which is an early stage of clinical research.^[1] Early-phase studies usually focus on safety first, and they may also begin to look for other signals that help plan later trials.^[1]

The brief summary says the study is designed to assess increasing doses of a single administration of VTX-002.^[1] The trial data also list VTx-002 Diluent as an intervention, but the main study focus remains VTX-002 in participants with ALS.^[1]

Why this trial matters

ALS is a serious disease, so early studies like this are important for learning whether a new treatment can be studied safely in this group.^[1] Because the trial is small and focused on safety, it is not designed to answer all questions about benefit.^[1] Instead, it provides early information that can help decide whether larger studies should be done later.^[1]

Table of Contents

• Trial overview
• Who is being studied
• Study design and phase
• What the trial measures
• What the study seeks to show

Trial overview

The clinical trial in the source data is an interventional study of ALLOGENEIC VEIN TISSUE SEGMENT, DECELLULARISED, WITH A FUNCTIONAL VALVE PERFUSED WITH AUTOLOGOUS PERIPHERAL BLOOD in patients with chronic venous insufficiency.^[1] The trial is authorised and includes 60 participants.^[1]

The study title describes it as a Phase II/III randomized controlled open-label trial, while the phase field lists Phase 4.^[1] This means the research is comparing treatment groups in a planned way and is focused on how well the treatment works and how safe it is in real patients.^[1]

Who is being studied

The target population is people with chronic venous insufficiency, especially those with severe CVI.^[1] The brief summary says the study is intended to show benefit in patients with severe disease, including effects on deep venous valve problems and on symptoms.^[1]

Chronic venous insufficiency is a long-term vein problem in which blood does not return to the heart properly.^[1] In this trial, the focus is on patients whose vein valves are not working well enough and who may have ongoing clinical signs and symptoms.^[1]

Study design and phase

This is an interventional study, which means participants receive the study treatment and the results are measured afterward.^[1] It is also described as randomized controlled, meaning participants are assigned to groups by chance so the treatment can be compared with control care.^[1]

The study is open-label, so the treatment assignment is not hidden from participants or researchers.^[1] The intervention listed is a drug named Personalized Tissue Engineered Vein, given as implantation.^[1]

What the trial measures

The main outcome is valve competency at 6 months after implantation compared with control, measured using Color Duplex Ultrasound to check for reflux.^[1] Valve competency means how well the valve closes and prevents blood from flowing backward.^[1]

The second main outcome is rVCSS score reduction at 6 months after implantation compared with control.^[1] The rVCSS is a score used to track clinical signs and symptoms of chronic venous insufficiency, so a drop in the score suggests improvement.^[1]

The study summary also says the researchers want to show disease-modifying efficacy and clinical efficacy.^[1] In simple terms, this means they want to see whether the treatment can change the course of the vein disease itself and also improve how patients feel and function.^[1]

What the study seeks to show

The first goal is to reduce deep venous valve pathology in patients with severe chronic venous insufficiency.^[1] Deep venous valve pathology means damage or disease in the valves inside deep veins, which can lead to backward blood flow.^[1]

The second goal is to reduce the clinical signs and symptoms of chronic venous insufficiency.^[1] This makes the trial important for understanding whether the treatment can help both the vein function and the patient’s day-to-day disease burden.^[1]

Table of Contents

• Trial overview
• Who can participate
• What is being measured
• Study design and treatment groups
• Trial status and size

Trial overview

The available trial is Phase 2 and is studying ANUMIGILIMAB in adults with sickle cell disease.^[1]

This is an interventional study, which means researchers are giving a study treatment and then watching what happens.^[1]

The brief study summary says the main objective is to assess the safety of ANUMIGILIMAB in adults with sickle cell disease.^[1]

Who can participate

The target population for this study is adults with sickle cell disease.^[1]

The source data does not list more detailed eligibility rules, such as age limits beyond adulthood or other health conditions that may affect joining the trial.

What is being measured

The main outcome is the number and percentage of participants with treatment-emergent adverse events, also called TEAEs.^[1]

These are health problems that start after the study treatment begins, or get worse during the study.^[1]

Researchers also measure adverse events of special interest, or AESIs, which are side effects that need extra attention in the study.^[1]

Another endpoint is clinically relevant changes from baseline in laboratory assessments and vital signs.^[1]

“Baseline” means the starting point before the study treatment is given.^[1]

Vital signs include basic body checks such as blood pressure and pulse, while laboratory assessments are tests of blood or other samples.^[1]

Study design and treatment groups

The study lists ANUMIGILIMAB given as a subcutaneous treatment, which means under the skin.^[1]

The trial also lists saline 0.9% as a comparison treatment.^[1]

This comparison helps researchers look at results in a group that does not receive the study drug in the same way.^[1]

Trial status and size

The study status is Authorised.^[1]

The planned enrollment is 63 participants, meaning the study aims to include 63 people.^[1]

At this stage, the main focus is on understanding safety in the target group rather than proving long-term benefit.^[1]

Table of contents

• Trial overview
• Who is being studied
• Treatments being compared
• Trial phase and design
• Endpoints being measured
• What the results will help answer

Trial overview

This clinical trial is testing “(R)-N-(4-([1,2,4]-TRIAZOLO[1,5-C]-PYRIMIDIN-7-YLOXY)-3-METHYLPHENYL)-5-((3,3-DIFLUORO-1-METHYLPIPERIDIN-4-YL)OXY)-6-METHOXYQUINAZOLIN-4-AMINE” in people with pretreated, unresectable, locally advanced or metastatic HER2-positive breast cancer.^[1] The study also includes people with or without central nervous system (CNS) metastases, which means cancer spread to the brain or spinal cord area.^[1]

Who is being studied

The target population is people who have already received treatment before and still have breast cancer that cannot be removed by surgery.^[1] The trial includes both locally advanced disease and metastatic disease, so it is focused on more advanced cancer stages.^[1]

People may be included whether or not they have CNS metastases.^[1] This makes the study relevant for patients whose cancer has spread beyond the breast, including the brain or spinal cord area.^[1]

Treatments being compared

The study compares two treatment combinations: “(R)-N-(4-([1,2,4]-TRIAZOLO[1,5-C]-PYRIMIDIN-7-YLOXY)-3-METHYLPHENYL)-5-((3,3-DIFLUORO-1-METHYLPIPERIDIN-4-YL)OXY)-6-METHOXYQUINAZOLIN-4-AMINE” with trastuzumab and capecitabine, versus tucatinib with trastuzumab and capecitabine.^[1]

The brief summary says the main aim is to compare the effectiveness of the two combinations, so the trial is not only looking at one treatment by itself.^[1] It is comparing one study combination against another active treatment combination already used in the trial.^[1]

Trial phase and design

This is a Phase 4 trial, which means it is a later-stage study done in a larger group of people.^[1] The study type is interventional, meaning researchers assign treatments and then measure outcomes.^[1]

The planned enrollment is 650 participants.^[1] The trial status is authorised.^[1]

Endpoints being measured

The main endpoint is progression-free survival in the full analysis set (PFS-FAS).^[1] Progression-free survival means the length of time during which the cancer does not get worse.^[1]

The full analysis set is the main group of participants used for analysis.^[1] This endpoint helps show whether one treatment combination keeps the cancer under control longer than the other.^[1]

What the results will help answer

The trial is designed to help answer whether the study combination with “(R)-N-(4-([1,2,4]-TRIAZOLO[1,5-C]-PYRIMIDIN-7-YLOXY)-3-METHYLPHENYL)-5-((3,3-DIFLUORO-1-METHYLPIPERIDIN-4-YL)OXY)-6-METHOXYQUINAZOLIN-4-AMINE” is more effective than the tucatinib-based combination in this patient group.^[1] It also helps researchers compare the safety and overall performance of the two treatment strategies in advanced HER2-positive breast cancer.^[1]

Table of Contents

• Trial overview
• Who can participate
• What is being measured
• Trial phase and design
• Why this trial matters

Trial overview

The available study is a Phase 3 trial of VMX-C001 in patients who are taking a Factor Xa direct oral anticoagulant and need urgent surgery or another procedure with a high risk of bleeding.^[1]

This trial compares VMX-C001 with usual pharmacological care, which means the standard medicine-based care used in this situation.^[1]

The study is authorised and planned for 439 participants.^[1]

Who can participate

The trial is for patients already receiving a Factor Xa inhibitor treatment who need an urgent intervention linked to a high risk of bleeding.^[1]

In simple terms, this means the study is focused on people who are on a blood thinner and suddenly need surgery or a procedure that could cause significant bleeding.^[1]

What is being measured

The main endpoint is the proportion of participants with good or excellent haemostatic efficacy during the required procedure.^[1]

Endpoint means the main result the researchers want to measure.^[1]

Haemostatic efficacy means how well bleeding is controlled during the procedure, and the result is judged by an independent blinded EAC, which is a separate expert group that does not know which treatment the participant received.^[1]

Trial phase and design

This is an interventional study, so researchers are giving a treatment and then checking the results.^[1]

Because it is Phase 3, the trial is meant to test the treatment in a larger group and compare it with standard care in a real clinical setting.^[1]

The study title also shows that the trial is looking at VMX-C001 versus usual pharmacological care in patients who need urgent surgery, with or without heparin.^[1]

Why this trial matters

Urgent surgery in people taking a Factor Xa anticoagulant can be difficult because bleeding control is very important.^[1]

This trial is designed to help answer whether VMX-C001 can improve bleeding control during these urgent procedures compared with the care that is usually used.^[1]

For patients, the key question is whether the treatment helps the medical team achieve good or excellent control of bleeding at the time of surgery or the procedure.^[1]

Table of contents

• Trial overview
• Who can join
• What is being measured
• Trial phase and design
• What the status means
• Related study details in the provided data

Trial overview

The trial data provided describes an interventional study, which means researchers give a study treatment and then observe what happens.^[1] The study is authorized and is planned for 275 participants.^[1] It is listed for people with solid tumors, which are cancers that form a mass in tissue or an organ.^[1]

The source data also lists IMA401 among the interventions in the trial record.^[1] The main study title in the provided record is for IMA402, but the intervention list includes IMA401, so the article focuses only on the trial information that is actually provided.^[1]

Who can join

The target population is patients with recurrent and/or refractory solid tumors.^[1] Recurrent means the cancer has come back after treatment, and refractory means the cancer is not responding well to treatment.^[1]

This tells us the study is meant for people with advanced cancer situations where standard treatment has not worked well enough or the disease has returned.^[1] The data does not give more detailed entry rules, so no other eligibility points can be confirmed from the source.^[1]

What is being measured

The main goals are to study safety, tolerability, and anti-tumor activity.^[1] Safety means how well the treatment can be given without causing harmful problems, while tolerability means how manageable the treatment is for patients.^[1]

The primary outcomes include dose-limiting toxicities, which are side effects serious enough to limit the dose that can be given.^[1] The study also tracks treatment-emergent adverse events and serious treatment-emergent adverse events, which are health problems that start or get worse after treatment begins.^[1]

Researchers also measure how often treatment must be interrupted, reduced, or stopped permanently because of side effects.^[1] In Phase II, they measure objective response rate, which is the number of patients whose tumors have a clear complete or partial response based on RECIST 1.1, a standard way to measure tumor change.^[1]

Trial phase and design

The study is a Phase 1/2 trial.^[1] Phase 1 studies usually focus on safety and finding the best dose range, while Phase 2 studies look more closely at whether the treatment may help the cancer.^[1]

The brief summary in the source says the study aims to determine the maximum tolerated doses and/or recommended doses for extensions in Phase Ia, and then to further characterize safety and anti-tumor activity in later parts of the trial.^[1] The trial also includes use of IMA402 alone or in combination with pembrolizumab in the title and brief summary, but the source data provided here does not give more detail about IMA401-specific treatment parts.^[1]

What the status means

The study status is Authorised.^[1] This means the trial has received permission to proceed according to the source record.^[1]

The enrollment number is 275, which is the planned number of participants in the study.^[1] This number helps show the size of the trial and how many people researchers expect to include.^[1]

Related study details in the provided data

The trial title in the source is for IMA402, a bispecific T cell-engaging receptor molecule targeting PRAME, but the intervention list also includes IMA401.^[1] Because the request is about IMA401, this article uses only the trial facts that are clearly present in the source data and does not add any extra details that are not stated.^[1]

The brief summary states the study is looking at monotherapy and combination use, but the provided record does not separate which parts apply specifically to IMA401.^[1] For that reason, the most reliable description is that IMA401 appears in the intervention list of an authorised Phase 1/2 study in solid tumors.^[1]

Table of Contents

• Trial overview
• Who the study is for
• What is being tested
• Study phase and goals
• What researchers measure

Trial overview

The study of GVV858 is an interventional study, which means researchers give a treatment and then observe the results.^[1] It is authorised and planned to enroll 85 people.^[1]

The trial title says it is studying GVV858 as a single agent or in combination with endocrine therapy in patients with HR+/HER2- breast cancer and other advanced solid tumors.^[1]

Who the study is for

The main condition listed in the trial data is advanced HR+/HER2- breast cancer.^[1] HR+/HER2- means the cancer has hormone receptors and does not have high HER2 levels, which helps define the cancer type.^[1]

The title also mentions other advanced solid tumors, so the study is not limited only to breast cancer in its wording.^[1] However, the condition field specifically highlights advanced HR+/HER- breast cancer.^[1]

What is being tested

GVV858 is being tested as a single agent, which means by itself, and also in combination with endocrine therapy.^[1] Endocrine therapy is treatment that changes hormone signals that can help some cancers grow.^[1]

The trial data lists combination partners including fulvestrant and letrozole, and it also lists hormone-lowering medicines such as goserelin and leuprorelin acetate.^[1] The brief summary says Phase I will assess GVV858 as a single agent and in combination with fulvestrant or letrozole.^[1]

Study phase and goals

This is a Phase 1/2 trial, which is an early stage of clinical research.^[1] Phase 1 usually focuses on safety and dose finding, while Phase 2 looks more closely at safety and tolerability in a larger group.^[1]

The brief summary says Phase I aims to assess safety and tolerability and to identify the recommended dose or dose range for further clinical evaluation.^[1] Phase II aims to further characterize the safety and tolerability of GVV858 in combination with fulvestrant.^[1]

What researchers measure

The main outcomes in Phase I include dose-limiting toxicities, adverse events, serious adverse events, and changes in lab values, vital signs, and electrocardiograms (ECGs).^[1] Dose-limiting toxicities are side effects that are serious enough to limit how much treatment can be given.^[1]

The study also measures tolerability by tracking dose interruptions, dose reductions, discontinuations, and dose intensity.^[1] In Phase II, the study continues to measure safety and tolerability using the same types of checks, including adverse events, serious adverse events, lab values, vital signs, and ECGs.^[1]

These outcomes help researchers understand whether GVV858 can be given safely and how well people can stay on treatment.^[1]

Table of contents

• Trial overview
• Conditions studied
• Study design and phase
• Who can participate
• What is measured in the trial
• Why this study matters

Trial overview

The listed clinical trial is NCT07259928, titled “Safety and Proof of Concept Study of ANXV (Annexin A5) in Patients With Diabetic Retinopathy or Retinal Vein Occlusion (NEXUS).”^[1] It is an authorised phase 2 study with an enrollment goal of 18 participants.^[1] The study is testing ANXV in people with eye disease to learn more about safety and early signs of benefit.^[1]

Conditions studied

This trial is focused on two eye conditions: diabetic retinopathy and retinal vein occlusion.^[1] Diabetic retinopathy is an eye disease linked to diabetes, and retinal vein occlusion is a blockage in a vein in the retina, the light-sensitive part of the eye.^[1] Both conditions can affect vision, which is why they are important targets for research.^[1]

Study design and phase

The study is an interventional trial, which means participants receive the study treatment so researchers can measure its effects.^[1] ANXV is given as a 6 mg intravenous infusion, meaning it is delivered through a vein.^[1] As a phase 2 study, it is designed to build on early research and look more closely at safety and possible benefit in a small group.^[1]

Who can participate

The trial is for participants who have either diabetic retinopathy or retinal vein occlusion.^[1] The available data do not list more detailed entry rules, so the main known target group is people with one of these two eye conditions.^[1] The study plans to include 18 people, which makes it a small early-stage trial.^[1]

What is measured in the trial

The main outcome measures are treatment-emergent adverse events (TEAEs) and serious adverse events (SAEs).^[1] These are used to track any medical problems that appear after treatment starts, especially problems that are severe or serious.^[1] The trial also measures the incidence and titre of anti-drug antibodies (ADA) before and after ANXV is given.^[1] This helps researchers see whether the body makes an immune response against the study treatment.^[1]

Why this study matters

This study is an early step in learning whether ANXV can be studied further in eye disease.^[1] Because it includes a small number of participants and focuses on safety, it is meant to provide early clinical information rather than final proof of effectiveness.^[1] The results may help researchers decide whether larger studies should be done in diabetic retinopathy or retinal vein occlusion.^[1]

Table of contents

• Trial overview
• Who the trial is for
• What is being tested
• Study phases and endpoints
• Trial status and size

Trial overview

The study NCT05786924 is an interventional study, which means researchers give a treatment and then measure what happens.^[1] It is testing S-241656 in people with cancers that have documented KRAS, BRAF, and other selected RAS/MAPK mutations.^[1]

The trial title shows that the research is focused on mutation-positive malignancies, meaning cancers with specific gene changes.^[1] The study is authorised and is designed to learn more about S-241656 in these patient groups.^[1]

Who the trial is for

This trial is for patients with malignancies that have documented KRAS, BRAF, or other selected RAS/MAPK mutations.^[1] In simple words, the study is not for all cancers; it is for cancers with certain gene changes that may help define who can take part.^[1]

The source data do not list every inclusion or exclusion rule, so the most important known target group is people with these mutation-positive cancers.^[1]

What is being tested

S-241656 is being studied both as monotherapy, which means treatment by itself, and in combination therapy, which means used together with other medicines.^[1] The combination treatments listed in the trial include several cancer medicines given by mouth or by vein.^[1]

The trial records show treatment combinations with medicines such as folinate de calcium, oxaliplatin, cetuximab, panitumumab, gemcitabine, irinotecan, and fluorouracil, among others.^[1] These names appear in the study record as part of the treatment plan being tested, not as a full treatment guide.^[1]

Study phases and endpoints

This is a Phase 1/2 trial.^[1] Phase 1 studies usually focus on safety and the right dose, while Phase 2 studies look more closely at whether the treatment shows early benefit.^[1]

In the dose escalation part, the main goal is to evaluate safety and tolerability, both when S-241656 is used alone and when it is used in combinations.^[1] The primary outcomes here include dose-limiting toxicities during the first 28-day cycle, as well as the number of adverse events and serious adverse events.^[1]

In the dose expansion part, the main goal is to evaluate antitumor activity, which means whether the treatment shows signs of working against the cancer.^[1] The primary endpoint in this part is objective response, meaning measurable tumor shrinkage or other clear improvement on study assessment.^[1]

Trial status and size

The trial status is listed as Authorised.^[1] The planned enrollment is 567 participants, which means the study aims to include that many people overall.^[1]

This is a fairly large early-phase study, so it is likely meant to gather both safety information and early signs of benefit across several mutation-positive cancer groups.^[1]

Table of Contents

• Trial overview
• Who was studied
• What the study measured
• Study phase and design
• Key trial details

Trial overview

One clinical trial studied SGN-ALPV in people with advanced solid tumors, which means cancers that form a solid mass and are not limited to the blood or bone marrow.^[1]

This was a Phase 1 trial, which is the first step of testing in people and usually focuses on safety and dose finding.^[1]

Who was studied

The study included people with several cancer types, such as gastroesophageal junction carcinoma, non-small cell lung cancer, gastric cancer, cervical cancer, ovarian cancer, and endometrial cancer.^[1]

The trial also included some germ cell tumors, including malignant ovarian germ cell tumor, malignant testicular germ cell tumor, and malignant extragonadal germ cell tumor, with some exclusions.^[1]

People with pure teratomas were excluded, and the study also excluded tumors with primary sites arising from the central nervous system.^[1]

What the study measured

The main goal was to evaluate the safety and tolerability of SGN-ALPV.^[1]

Researchers measured the type, number, and severity of adverse events, which are health problems that happen during a study, whether or not they are caused by the treatment.^[1]

The study also tracked laboratory abnormalities, which are unusual blood test or other lab results, and dose-limiting toxicities, meaning side effects that may stop a dose from being increased.^[1]

Another goal was to find the maximum tolerated dose and a recommended dose and schedule for later parts of the study.^[1]

Study phase and design

The trial was an interventional study, which means participants received the study treatment directly as part of the research.^[1]

The study was completed and enrolled 254 people.^[1]

SGN-ALPV was given by intravenous administration, which means it was delivered through a vein.^[1]

Key trial details

• Trial ID: NCT05229900.^[1]
• Phase: Phase 1.^[1]
• Status: Completed.^[1]
• Enrollment: 254 participants.^[1]
• Main focus: Safety, tolerability, dose limits, and dose selection for future study.^[1]

Table of Contents

• Trial overview
• Who can join the study
• What is being tested
• Trial phase and status
• Outcomes measured
• Patient-friendly terms

Trial overview

The available study is an interventional clinical trial, which means participants receive a study treatment and the results are compared with another group.^[1] It is designed to assess the efficacy and safety of a vaccine for dust mite and Blomia tropicalis allergy.^[1]

The trial is authorised and includes 120 participants.^[1]

Who can join the study

The trial is for people aged 12 to 65 years who have moderate-to-severe persistent allergic rhinitis/rhinoconjunctivitis.^[1] People may also have mild-to-moderate controlled allergic asthma, as long as it is controlled.^[1]

This means the study is focused on patients with allergy problems that affect the nose and eyes, and in some cases the lungs as well.^[1]

What is being tested

The study treatment is BLOMIA TROPICALIS POLYMERIZED EXTRACT as part of a suspension for injection given under the skin.^[1] The active treatment contains D.pteronyssinus/D.farinae/B.tropicalis polymerized extracts 10,000 TU/mL, and it is compared with a placebo that has the same solution and presentation but no active ingredients.^[1]

The trial is testing whether this investigational medicinal product can help as an aetiological treatment, meaning a treatment aimed at the cause of the allergy.^[1]

Trial phase and status

This study is a Phase 3 trial.^[1] Phase 3 trials are later-stage studies that usually look at how well a treatment works in a larger group of patients while continuing to watch safety.^[1]

The current status is authorised.^[1]

Outcomes measured

The main outcome is the Rhinoconjunctivitis Combined Symptom and Medication Score (RCSMS).^[1] This score combines how bad the symptoms are and how much medication is used, so researchers can judge overall control of the allergy.^[1]

The score is measured over 4 weeks after one year of treatment, and it is recorded in the participant’s diary.^[1]

Patient-friendly terms

• Placebo means a look-alike treatment used for comparison, but it does not contain active ingredients.^[1]
• Subcutaneous injection means the treatment is given under the skin.^[1]
• Allergic rhinitis/rhinoconjunctivitis means allergy symptoms in the nose, and sometimes the eyes too.^[1]
• Controlled asthma means asthma that is stable and not badly affecting the person most of the time.^[1]
• Participant diary is the record used by the study volunteer to write down symptoms and other study information.^[1]

Table of Contents

• Trial overview
• Who is being studied
• Study design and phase
• What is being measured
• Why this study matters

Trial overview

The available trial is NA2C-TEP-IRM, which is listed as an interventional study in neurology.^[1] It is authorised and planned to enroll 165 people.^[1]

The study uses the radiotracer [¹¹C]ORM-13070 to evaluate the effect of normal aging and Parkinson’s disease on the availability of α₂C-adrenergic receptors in the human brain.^[1]

Who is being studied

The brief summary says the study is focused on normal aging and Parkinson’s disease.^[1] The trial data do not give full participation rules, but they show that the target population includes people relevant to these two neurology groups.^[1]

Because the study is about brain imaging, participants are being assessed with PET and MRI scans rather than with a treatment plan for symptom control.^[1]

Study design and phase

This is a Phase 2 trial.^[1] Phase 2 studies are usually used to look more closely at a research question in a defined group after earlier work has already started the testing process.

The trial is interventional, which means the research team gives the study product and then measures the results.^[1] In this study, the intervention is listed as a drug injection of [11C]ORM-13070 at 350 MBq.^[1]

What is being measured

The primary outcome uses PET data to calculate binding potential (BPND) parametric maps with compartmental modelling techniques.^[1] In simple terms, this means the scan data are turned into maps that help researchers estimate how strongly the tracer is associated with the target in the brain.^[1]

The MRI outcome measures the locus coeruleus, a small brain region, using a neuromelanin-sensitive MRI sequence and then calculates signal intensity for each participant.^[1] Neuromelanin-sensitive MRI means a scan method designed to highlight a natural brain pigment linked with certain nerve cells.^[1]

Together, these outcomes are meant to compare how aging and Parkinson’s disease may change receptor availability and related brain signals.^[1]

Why this study matters

This trial is not described as a treatment study for symptoms; instead, it is a research study about brain biology in people with and without Parkinson’s disease.^[1] The results may help researchers better understand how the noradrenergic system changes with age and disease, based on the trial’s stated objective.^[1]

Only one trial record was provided, so the overall clinical trial picture for 1-[[(3S)-2,3-DIHYDRO-1,4-BENZODIOXIN-3-YL]METHYL]-4-[3-((11C)METHOXYMETHYL)-2-PYRIDINYL]PIPERAZINE is limited to this Phase 2 neurology imaging study.^[1]

Table of contents

• Trial overview
• Study design and phases
• Who can participate
• What is being measured
• How results are judged
• Why this study matters

Trial overview

This article is about one clinical trial of HUMAN FIBROBLASTS for refractory wounds, which are wounds that are hard to heal.^[1] The study is interventional, which means the researchers give a study treatment and then watch what happens.^[1]

The trial is authorised and plans to include 52 people.^[1] It uses topical use, meaning the treatment is applied on the skin or wound area rather than taken by mouth.^[1]

Study design and phases

This is a Phase 1/2 study.^[1] Phase 1 studies usually focus on safety first, while Phase 2 studies look more closely at whether the treatment may help.^[1]

The study has two parts.^[1] In the first part, the team uses an open-label, dose escalation design to test two different doses and find the best dose for the next part.^[1] In the second part, the selected dose is tested further to assess efficacy, which means how well it works, and to confirm safety and tolerability.^[1]

Open-label means the study is not blinded, so the participants and investigators know what is being used.^[1] Dose escalation means the study checks more than one strength in steps before choosing the best one.^[1]

Who can participate

The trial is designed for people with chronic refractory wounds.^[1] The source data do not give more detailed entry rules, such as age limits or other medical requirements.^[1]

Because the study focuses on wounds that do not heal easily, it is meant for patients who have a long-lasting wound problem and need new treatment options.^[1]

What is being measured

The main safety measures include Treatment Emergent Adverse Events, also called TEAEs, which are problems that happen after the product is applied.^[1] The study also checks changes in physical examination findings, vital signs, 12-lead ECG, blood tests, and urine tests.^[1]

Another safety measure is the investigator’s overall tolerability score on a 5-point Likert scale, which is a simple rating scale from very well tolerated to not tolerated at all.^[1]

The efficacy measures focus on wound healing and symptom relief.^[1] These include change in ulcer size, change in wound area in square centimeters, change in the Wound Bed Score, and change in wound pain using a Visual Analogue Scale or VAS, which is a pain rating scale.^[1]

The study also measures the number of responders, meaning people whose ulcer area is reduced by at least 50%, the time to 50% wound reduction, the time to healing if healing happens, and changes in the Wound-QoL-14 questionnaire, which looks at quality of life related to the wound.^[1]

How results are judged

The wound size outcome is scored in six categories, from unchanged to fully healed.^[1] This helps the researchers see not only whether a wound gets smaller, but also whether it closes completely.^[1]

The study also looks at the investigator’s satisfaction with the product’s efficacy using a 5-point Likert scale, which helps show how the treatment performs in real clinical use.^[1] Together, these results are meant to give a full picture of safety, healing progress, pain, and patient impact.^[1]

Why this study matters

People with refractory wounds often need new options because their wounds are slow to improve.^[1] This trial is important because it first tries to find the best dose and then checks whether the chosen dose may help wounds heal better.^[1]

The study is focused on practical outcomes that matter to patients, such as wound size, pain, healing time, and quality of life.^[1] That makes it a patient-centered trial, with both safety and everyday wound improvement in view.^[1]

Table of contents

• Overview of the trials
• Who the trials are for
• Trial phases and study design
• Main endpoints and what they mean
• Trial summary

Overview of the trials

These clinical trials are studying KAI-9531 in people living with obesity, and in one study, people with obesity or overweight and diabetes.^[1][2][3]

The studies are designed to look at efficacy (how well a treatment works) and safety (how well it is tolerated), using comparisons with semaglutide or placebo.^[1][2][3]

Who the trials are for

One trial is for participants living with obesity who do not have diabetes.^[1]

Another trial is for participants living with obesity or overweight and diabetes.^[2]

The third trial is for participants living with obesity or overweight with weight-related comorbidities and who do not have diabetes.^[3]

A comorbidity is another health problem that happens along with the main condition.^[3]

Trial phases and study design

All three studies are Phase 3 trials, which means they are late-stage studies in larger groups of people.^[1][2][3]

Each study is interventional, meaning researchers assign a treatment and then measure the results.^[1][2][3]

In one trial, KAI-9531 is compared with semaglutide and placebo.^[1]

In the other two trials, KAI-9531 is compared with placebo.^[2][3]

Main endpoints and what they mean

The main outcome in two studies is percent change in body weight from the start of the trial to Week 76.^[1][3]

The study in participants with diabetes also measures change in hemoglobin A1c at Week 76.^[2]

Hemoglobin A1c is a blood test that shows average blood sugar over time, so it helps researchers see whether blood sugar control changes during the study.^[2]

The trial comparing KAI-9531 with semaglutide is designed to show that KAI-9531 is better than semaglutide and placebo for percent change in body weight.^[1]

The study in people with diabetes is designed to show that KAI-9531 is better than placebo for both body weight change and HbA1c change.^[2]

Trial summary

Table of contents

• Trial overview
• Condition studied and who can join
• Treatment and comparison
• Study phase and design
• What the trial measures
• Why this trial matters for patients

Trial overview

The available trial data show one authorised study of ZAMPILIMAB in people with idiopathic pulmonary fibrosis, also called IPF^[1]. The study title says it is looking for an efficacious and safe dose of CHF10067, which is identified as zampilimab in the source data^[1].

This is an interventional clinical trial, which means researchers give a study treatment and then measure the results^[1]. The trial is authorised and plans to enrol 235 participants^[1].

Condition studied and who can join

The trial is for participants with idiopathic pulmonary fibrosis^[1]. IPF is a lung disease that causes scarring and can reduce breathing ability; the trial data do not provide more detail about symptoms or disease stage^[1].

The source data do not list full entry rules such as age limits, test results, or previous treatments^[1]. Based on the available information, the target population is people living with IPF^[1].

Treatment and comparison

The study intervention includes ZAMPILIMAB given by intravenous infusion, which means it is delivered into a vein^[1]. The trial data also mention 0.9% sodium chloride aqueous solution for IV infusion as the comparison treatment^[1].

The brief summary says the study is evaluating two dose strengths of CHF10067 and comparing them with placebo in the entire study population^[1]. In simple words, the trial is checking whether different doses work better than a non-active comparison treatment^[1].

Study phase and design

This is a Phase 2 study^[1]. Phase 2 trials usually focus on whether a treatment may help and continue to watch safety in a larger group than early studies, but the source data only confirm the phase and do not add more design details^[1].

The study is listed as interventional and authorised, with an expected enrolment of 235 participants^[1]. The available data do not describe randomisation, masking, or how many study groups there are^[1].

What the trial measures

The primary outcome is measured at Week 24^[1]. The main endpoint is the change from baseline in percent predicted forced vital capacity, or ppFVC, compared with placebo in the whole study population^[1].

Forced vital capacity is a lung function test that shows how much air a person can breathe out after taking a deep breath^[1]. ‘Percent predicted’ means the result is compared with what would be expected for someone of similar age, sex, height, and background^[1].

Why this trial matters for patients

For people with IPF, lung function can slowly get worse over time, so studies that measure breathing tests are important^[1]. This trial is designed to see whether ZAMPILIMAB can improve or preserve lung function better than placebo over 24 weeks^[1].

Because only one trial is provided in the source data, the current picture is limited to this Phase 2 study in IPF^[1]. The most important facts from the available record are the condition studied, the authorised status, the planned enrolment of 235 participants, and the focus on ppFVC at Week 24^[1].

Table of contents

• Trial overview
• Who can participate
• Study design and phase
• What is being measured
• What the trial is trying to learn
• Key terms explained

Trial overview

The available trial data describe one interventional study of 3-[(3AS,6AR)-5-{5-CHLORO-2-[(1-METHYL-1H-PYRAZOL-4-YL)AMINO]PYRIMIDIN-4-YL}-3A-METHYLHEXAHYDROPYRROLO[3,4-C]PYRROL-2(1H)-YL]-3-OXOPROPANENITRILE in people with prurigo nodularis, a condition with severe itching and skin nodules. The study is authorised and plans to enroll 135 participants.^[1]

The study title says it is a randomized, double-blind, placebo-controlled, and dose-ranging phase 2 trial. In simple words, participants are assigned by chance, neither the participants nor the study team know who gets which treatment, and the trial compares the study drug with a placebo while checking more than one dose.^[1]

Who can participate

The source data say the trial is for adult participants with prurigo nodularis.^[1] No other eligibility details are provided in the trial record, so the available information does not list extra requirements such as past treatments, disease severity, or other health conditions.

• Adults only: The study is not described as open to children or teenagers.^[1]

• Specific condition: Participants must have prurigo nodularis, because that is the condition being studied.^[1]

Study design and phase

This is a phase 2 study, which usually means researchers are looking for early signs that the treatment may help, while still watching safety closely.^[1] The trial is also placebo-controlled, so the study drug is compared with a treatment that looks the same but does not contain the active substance.^[1]

The study is dose-ranging, which means more than one dose is being evaluated. The intervention list mentions placebo and 3-[(3AS,6AR)-5-{5-CHLORO-2-[(1-METHYL-1H-PYRAZOL-4-YL)AMINO]PYRIMIDIN-4-YL}-3A-METHYLHEXAHYDROPYRROLO[3,4-C]PYRROL-2(1H)-YL]-3-OXOPROPANENITRILE given orally at 120 mg.^[1]

What is being measured

The main endpoint is the percent change from baseline in the weekly average Peak pruritus-numeric rate scale (PP NRS) at Week 16.^[1] In patient-friendly language, this means the study is checking how much the worst itching score changes after treatment compared with the starting point.

Because the endpoint focuses on itch, the trial is mainly trying to learn whether the treatment can reduce itching in people with prurigo nodularis.^[1]

What the trial is trying to learn

The brief summary says the study aims to evaluate the treatment efficacy of ICP-332 versus placebo in adult participants with PN.^[1] ICP-332 is the study name used in the trial title for 3-[(3AS,6AR)-5-{5-CHLORO-2-[(1-METHYL-1H-PYRAZOL-4-YL)AMINO]PYRIMIDIN-4-YL}-3A-METHYLHEXAHYDROPYRROLO[3,4-C]PYRROL-2(1H)-YL]-3-OXOPROPANENITRILE.^[1]

From the source data, the key goals are to compare the study drug with placebo, look at different doses, and measure whether itching improves by Week 16.^[1] The record also shows that safety is part of the study title, so safety is being assessed along with efficacy.^[1]

Key terms explained

Randomized means treatment is assigned by chance, which helps make the comparison fair.^[1] Double-blind means neither the participants nor the study team know who is receiving the active treatment or placebo during the study.^[1]

Placebo means a look-alike treatment with no active substance, used to help show whether the study drug works better than no active treatment.^[1] Baseline means the starting measurement before treatment begins.^[1]

Primary outcome means the main result the researchers plan to measure first.^[1] Enrollment means the number of people planned for the study, which here is 135.^[1]

Table of Contents

• Trial overview
• Who is being studied
• What is being measured
• Trial design and treatment groups
• Why this study matters

Trial overview

The available clinical trial for GXV813 is a Phase 2 interventional study called STAR-1.^[1] It is authorised and includes 142 participants.^[1]

The study is designed to assess the safety, tolerability, and treatment response of GXV813 in people with schizophrenia.^[1] The trial compares GXV813 with placebo to see whether the study drug improves symptoms.^[1]

Who is being studied

This study focuses on hospitalized adults with schizophrenia who are having an acute episode.^[1] The trial summary says the participants are adult inpatients diagnosed according to DSM-5 criteria.^[1]

In simple terms, this means the study is looking at people who are currently in the hospital and whose symptoms are active enough to need close care.^[1]

What is being measured

The main endpoint is the change from baseline in PANSS total score at 6 weeks.^[1] Baseline means the starting point before treatment begins.^[1]

PANSS stands for Positive and Negative Symptom Scale, which is a rating tool used to measure schizophrenia symptoms.^[1] A change in this score helps researchers see whether symptoms improve, worsen, or stay the same over time.^[1]

Trial design and treatment groups

The study is interventional, which means researchers assign the treatment rather than just observing what happens.^[1] The interventions listed are GXV813 given orally and placebo in hard gelatin capsule form.^[1]

Placebo is a comparison treatment that does not contain the active study drug.^[1] Using placebo helps researchers judge whether any symptom change is due to GXV813 rather than chance or other factors.^[1]

Why this study matters

Schizophrenia can affect both positive symptoms, such as hallucinations or delusions, and negative symptoms, such as low motivation or reduced speech.^[1] This trial is important because it focuses on both types of symptoms in a hospital setting where people may need close monitoring.^[1]

Because the study is in Phase 2, it is part of the process of learning whether GXV813 may help people with schizophrenia and how it performs in a larger patient group.^[1]

Table of contents

• Trial overview
• Who can join
• What is being measured
• Trial design and phase
• Key points for patients

Trial overview

The available study is an interventional study, which means participants receive a study treatment so researchers can observe the results.^[1] It is testing a new lipase product called NHS7108 and comparing it with pancrelipase in adults with exocrine pancreatic insufficiency.^[1] The study status is Authorised, and the planned enrollment is 44 participants.^[1]

Who can join

The trial is for adult participants with exocrine pancreatic insufficiency, also called EPI.^[1] EPI is the condition the study is focused on, so the trial is not described as being for children or for other diseases.^[1]

What is being measured

The main safety measure is the number of participants who report one or more adverse events, which means unwanted medical problems during the study.^[1] The study also checks changes from baseline, which means changes compared with the starting point, in safety tests such as clinical laboratory tests, vital signs, 12-lead ECG, and physical examination after 14 days of NHS7108 treatment.^[1]

Another outcome is the change in coefficient of nitrogen absorption (CNA) after 14 days of NHS7108 treatment.^[1] CNA is a measure linked to how well the body absorbs nitrogen from food, which helps researchers judge digestion-related benefit in this study.^[1]

Trial design and phase

This is a Phase 2 trial.^[1] Phase 2 studies usually look carefully at safety and also explore whether a treatment may start to show benefit.^[1] In this study, NHS7108 is given daily for 14 days, and the trial compares it with Zenpep delayed-release capsule, which is listed as pancrelipase in the source data.^[1]

Key points for patients

• The study is focused on people with EPI, a condition where the pancreas does not make enough digestive enzymes.^[1]

• The main question is whether NHS7108 is safe and whether it may help digestion-related outcomes over a short 14-day period.^[1]

• Researchers are watching for adverse events and also checking standard safety tests such as blood tests, heart tracing, and physical exam findings.^[1]

• The study includes a comparison with pancrelipase, so researchers can see how the new product performs against an existing treatment listed in the trial data.^[1]

• Because the enrollment is 44 participants, this is a relatively small study designed for early research rather than a large final proof of benefit.^[1]

Table of Contents

• Clinical trial overview
• Who the study is for
• How the trial is designed
• Main outcome being measured
• Important terms explained

Clinical trial overview

The available study of VAMIFEPORT TRIHYDROCHLORIDE is titled “Efficacy and safety of vamifeport in adult subjects with HFE-related hereditary hemochromatosis.”^[1] It is an interventional trial, which means researchers are giving a study treatment and comparing results instead of only observing people.^[1]

The trial is authorised and is in Phase 2.^[1] Phase 2 studies usually focus on whether a treatment may help and continue to check safety in a specific patient group.

Who the study is for

This trial is for adult subjects with HFE-related hereditary hemochromatosis.^[1] This condition is also described in the source as homeostatic iron regulator gene-related hereditary hemochromatosis.^[1]

Hereditary hemochromatosis is an inherited iron disorder, meaning it runs in families and can lead to too much iron building up in the body. The study population is limited to adults, so children are not part of the trial description provided.

How the trial is designed

The study compares CSL624, listed as the trial drug, with a placebo capsule that matches vamifeport.^[1] A placebo is a look-alike treatment with no active medicine, used so researchers can better see whether the study drug makes a difference.

The planned enrollment is 81 participants.^[1] Enrollment means the number of people expected to join the study.

Main outcome being measured

The primary outcome is the change from baseline in magnetic resonance imaging (MRI)-based liver iron concentration (LIC).^[1] Baseline means the first measurement taken before treatment starts, and change from baseline means how much that number goes up or down later in the study.

MRI is a scan that creates pictures inside the body, and in this trial it is used to measure how much iron is in the liver without surgery.^[1] Liver iron concentration, or LIC, is the amount of iron stored in the liver.^[1]

The brief study summary says the purpose is to assess the effect of VAMIFEPORT TRIHYDROCHLORIDE treatment on MRI-based liver iron concentration in adults with HFE-related hereditary hemochromatosis.^[1]

Important terms explained

Interventional study means the researchers actively give a treatment and then measure the results.^[1]

Phase 2 means the study is past the first safety-only stage and is now looking more closely at possible benefit while still watching safety.

Placebo means an inactive capsule used for comparison so the study can be more reliable.^[1]

Authorised means the trial has been approved to proceed.^[1]

Table of Contents

• Clinical trial overview
• Who is being studied
• What the study measures
• Study design and phase
• Why this research matters

Clinical trial overview

The available trial for “[18F]CPFPX” is an interventional study, which means researchers are using a planned test procedure and measuring the results.^[1] It is focused on neurology and specifically on people with drug-resistant epilepsy, while also including healthy subjects for comparison.^[1]

The study title says it is about the impact of epilepsy on the brainstem adenosine pathway and how this relates to arousal and respiratory reactivity.^[1] The brief summary states that the trial compares brain imaging findings with [18F]-CPFPX PET in brainstem structures involved in respiratory regulation under a hypercapnic condition.^[1]

Who is being studied

This trial includes patients with drug-resistant epilepsy and healthy subjects.^[1] The healthy group is used as a comparison group, so researchers can see whether the brain imaging results are different in epilepsy.^[1]

The trial data do not give more detailed eligibility rules, such as age limits or other health requirements.^[1] The enrollment is 50 participants in total.^[1]

What the study measures

The main outcome is the comparison of [18F]-CPFPX BPND in brainstem structures involved in respiratory regulation under hypercapnic condition in patients with drug-resistant epilepsy and healthy subjects.^[1] BPND is a PET scan measurement that helps describe how much tracer is bound in a brain area.^[1]

In simple terms, the study is trying to see whether the brainstem pattern seen on PET imaging changes when carbon dioxide levels are increased, and whether this differs between groups.^[1] The trial also links these findings to arousal and breathing-related responses.^[1]

Study design and phase

The trial is listed as Phase 2.^[1] Phase 2 studies are early clinical studies that test how a study procedure performs in people and what it can measure.^[1]

The status is Authorised, which means the study has been approved to move forward.^[1] The intervention listed is [18F]CPFPX given by injection at 275 MBq.^[1]

Why this research matters

This research may help explain how epilepsy affects brain areas that control breathing and alertness.^[1] It may also help researchers compare patients with healthy subjects using a brain imaging method that can show differences in specific brainstem structures.^[1]

Because the study focuses on a breathing challenge, it is aimed at understanding respiratory regulation, which means how the body keeps breathing stable.^[1] The trial does not provide results yet, so its purpose is mainly to measure and compare brain imaging findings.^[1]

Table of contents

• Trial overview
• Study design and participants
• What was measured
• Trial status and size
• Patient-friendly terms

Trial overview

This clinical research studied [14C] DC-806 in a Phase 1 setting.^[1]

The trial focused on healthy male participants and looked at how the study drug was removed from the body after one oral dose.^[1]

The brief summary says the study aimed to assess the rate and routes of excretion, including mass balance, and to assess pharmacokinetics in whole blood and plasma.^[1]

Study design and participants

This was an interventional study, which means researchers gave the study drug and then measured the body’s response.^[1]

The trial enrolled 8 participants and was completed.^[1]

The treatment listed in the source data was oral DC-806 and oral [14C]-DC-806, given as a single dose in the study summary.^[1]

What was measured

The main outcomes included how much of the total radioactive material and DC-806 was recovered in urine and feces.^[1]

The study also measured pharmacokinetic values in whole blood and plasma, including Cmax (the highest level), tmax (the time to reach the highest level), kel (the rate of removal), t1/2 (half-life), and AUC (total exposure over time).^[1]

For DC-806, the study also listed CL/F and Vz/F, which are measurements used to describe how the body clears a drug and how it spreads in the body.^[1]

For total radioactive material, the study measured whole blood to plasma ratios for Cmax and AUC0-inf, which help compare levels in different blood samples.^[1]

Trial status and size

The study status was Completed.^[1]

The enrollment was small, with only 8 healthy male participants, which is typical for an early Phase 1 study focused on how the body handles a substance rather than on disease treatment.^[1]

Patient-friendly terms

Excretion balance means checking where the study material goes after dosing and how much leaves the body through urine and feces.^[1]

Pharmacokinetics means how the body absorbs, moves, and removes the study drug over time.^[1]

Metabolism means how the body changes the study drug into other substances called metabolites.^[1]

Healthy participants are people without the disease being studied, used here so researchers can see the drug’s basic behavior in the body.^[1]

Table of Contents

• Trial overview
• Who is being studied
• Trial design and treatment groups
• What the study measures
• Trial status and size
• What this means for patients

Trial overview

The available trial data describe a Phase 2 study of HUMAN IGG4 KAPPA MONOCLONAL ANTIBODY AGAINST PLATELET-DERIVED GROWTH FACTOR SUBUNIT B in adults with pulmonary arterial hypertension (PAH).^[1] The brief study summary says the goal is to evaluate the effect of the study treatment on pulmonary vascular resistance (PVR).^[1]

Who is being studied

This trial is for adult participants with PAH.^[1] The source data do not give more detailed inclusion or exclusion rules, so the full list of who can join is not available here.

Trial design and treatment groups

The study is listed as an interventional trial, which means researchers assign a treatment and then measure the results.^[1] The intervention list includes HUMAN IGG4 KAPPA MONOCLONAL ANTIBODY AGAINST PLATELET-DERIVED GROWTH FACTOR SUBUNIT B and a placebo group, which helps compare outcomes fairly.^[1] The intervention routes shown in the source are intravenous, subcutaneous, and intramuscular, but the data do not explain how these are used in the full study plan.^[1]

What the study measures

The main outcome is the change from baseline in pulmonary vascular resistance (PVR).^[1] Baseline means the starting measurement before treatment begins, and PVR is a measure of how hard it is for blood to flow through the lung blood vessels.^[1] In simple terms, the study is checking whether the treatment changes the pressure or resistance in the lung circulation compared with the starting point.^[1]

Trial status and size

The trial status is listed as Authorised.^[1] The planned enrollment is 99 participants, which means up to 99 people are expected to be included in the study.^[1]

What this means for patients

For people living with PAH, this study is part of early-to-mid stage clinical research looking for signs that HUMAN IGG4 KAPPA MONOCLONAL ANTIBODY AGAINST PLATELET-DERIVED GROWTH FACTOR SUBUNIT B may affect lung blood flow measurements.^[1] Because the trial is Phase 2, it is mainly focused on learning more about possible benefit while continuing to gather research information.^[1] The source data do not report final results, so the trial should be seen as an ongoing or planned research effort rather than a proven treatment answer.^[1]

Table of contents

• Trial overview
• Who is being studied
• How the trials are designed
• What the trials measure
• Target populations and treatment groups
• Patient-friendly explanation of key terms

Trial overview

Two Phase 3 clinical trials are investigating LOLIUM PERENNE POLLEN, DEPIGMENTED POLYMERIZED EXTRACT in people with pollen allergy symptoms.^[1][2]

One trial studies people with allergic rhinoconjunctivitis, with or without asthma, linked to grass and olive pollen sensitization.^[1] The other studies people with allergic rhinoconjunctivitis, with or without controlled asthma, linked to grass pollen allergy.^[2]

Who is being studied

The first study, GOES, includes people with clinically relevant sensitisation to grass and olive pollen.^[1] The condition studied is allergic rhinoconjunctivitis with or without asthma.^[1]

The second study, GIRA, includes people with allergic rhinoconjunctivitis with or without controlled asthma.^[2] This means the study is focused on patients whose asthma is already under control if they have asthma.^[2]

How the trials are designed

Both studies are interventional, which means researchers give a study treatment and then measure the results.^[1][2]

Both trials compare active treatment with placebo, which is the solvent used in the investigational product formulation and acts as a comparison treatment.^[1][2]

In the GOES study, the treatment arm includes Depigoid DUO Grass-Mix/Olea, and the study also uses conjunctival provocation tests with grass mix and Olea europaea.^[1]

In the GIRA study, the treatment arms include Depigoid Grass-Mix and Depigoid FORTE Grass-Mix, and the study also uses a conjunctival provocation test with grass mix.^[2]

What the trials measure

The main outcome in both studies is the combined symptom and medication score, also called cSMS, measured on a 0 to 6 scale during the peak pollen season.^[1][2]

This score combines allergy symptoms and the medicines used to control them.^[1][2] In the trial data, symptom items include runny nose, sneezing, itchy nose, nasal congestion, itchy eyes, and tearing.^[1]

The GOES study measures cSMS at the peak of grass and olive pollen season after at least 8 injections of treatment.^[1] The GIRA study measures cSMS at the peak of grass pollen season after at least 8 injections of treatment.^[2]

The GIRA study also has an open-label phase, where it measures the change in the amount of allergen needed to obtain a positive conjunctival provocation test after the pollen season compared with baseline.^[2]

Target populations and treatment groups

The GOES trial plans to enroll 343 participants.^[1] It focuses on people with allergy to both grass and olive pollen, with or without asthma.^[1]

The GIRA trial plans to enroll 324 participants.^[2] It focuses on people with grass pollen allergy, with or without controlled asthma.^[2]

These studies are designed to compare different treatment strengths and placebo, so researchers can see whether the active treatment improves allergy control during pollen season.^[1][2]

Patient-friendly explanation of key terms

Allergic rhinoconjunctivitis means allergy symptoms in the nose and eyes, such as sneezing, congestion, itching, and watery eyes.^[1][2]

Controlled asthma means asthma that is already managed well enough to meet the study rules.^[2]

Peak pollen season is the time when pollen levels are highest and symptoms are often worse.^[1][2]

Open-label phase means people know what treatment they are receiving.^[2]

Positive conjunctival provocation test means the eye reacts to a small amount of allergen during testing.^[2]

Table of Contents

• Trial overview
• Who can join the study
• Study design and treatment groups
• What the study is measuring
• What this trial means for patients

Trial overview

The available trial is called EASE-AKI and is studying SP16-3M in people with chronic kidney disease who are having elective cardiac surgery with a heart-lung machine.^[1] The study is Phase 2, which means it is looking more closely at whether the treatment may help and whether it appears safe in this group.^[1]

This is an interventional study, so participants receive a study treatment and the researchers compare outcomes between groups.^[1] The trial status is Authorised, and the planned enrollment is 120 participants.^[1]

Who can join the study

The trial is designed for at-risk subjects with chronic kidney disease who are going to planned heart surgery using a heart-lung machine.^[1] The brief summary says the target group includes participants with CKD 2-3b, which means a moderate range of long-term kidney disease.^[1]

The listed conditions for the study are Chronic Kidney Disease, Valvular Disease, and Cardiovascular Disease.^[1] In simple terms, this means the trial is focused on people having heart surgery who already have kidney problems and related heart or blood vessel disease.^[1]

Study design and treatment groups

The trial is described as prospective, randomized, double-blind, and placebo-controlled.^[1] Prospective means the study follows people forward in time, randomized means participants are assigned by chance, double-blind means neither the participants nor the study team know who gets which treatment, and placebo-controlled means one group receives a comparison treatment that does not contain the active study drug.^[1]

The intervention list shows a comparison between a subcutaneous injection of a placebo-like drug entry and SP16-3M given by subcutaneous injection at 12 mg.^[1] The study title also states that the trial is testing efficacy and safety for preventing acute kidney injury after surgery.^[1]

What the study is measuring

The main safety endpoint is the frequency of adverse events and serious adverse events within 72 hours after the index surgery.^[1] This means the researchers are watching for any medical problems after the operation, especially in the first three days.^[1]

The main efficacy endpoint is the number of participants who develop CSA-AKI during the hospital stay, defined as KDIGO stage 1 or higher.^[1] CSA-AKI means kidney injury linked to cardiac surgery, and KDIGO is the rule set used to grade how serious the kidney injury is.^[1]

The brief summary also says the goal is to see whether SP16-3M can prevent CSA-AKI as defined by KDIGO criteria in participants with CKD 2-3b undergoing planned cardiac surgery.^[1]

What this trial means for patients

For patients, this study is mainly about finding out whether SP16-3M can lower the risk of kidney injury around the time of heart surgery.^[1] The study is focused on a specific high-risk group, so the results may be most useful for people with chronic kidney disease who need elective cardiac surgery.^[1]

Because the trial is still in Phase 2, it is not a final proof of benefit, but an important step to learn more about safety and possible effect in the target population.^[1]

Table of Contents

• Overview of the ATIRMOCICLIB study
• Who the trial is for
• What treatment combinations are being studied
• What the researchers are measuring
• Trial phase and study design
• Key patient-focused points

Overview of the ATIRMOCICLIB study

The clinical trial data describe an interventional study called MORPHEUS-panBC, which is evaluating multiple treatment combinations in people with metastatic breast cancer.^[1] The study status is Authorised and the planned enrollment is 325 participants.^[1]

This trial includes metastatic breast cancer across several subtypes, including triple negative breast cancer (TNBC), hormone receptor positive breast cancer (HR+ BC), and HER2-positive or HER2-low breast cancer (HER2+/HER2-low BC).^[1]

Who the trial is for

The study is designed for patients with metastatic breast cancer, meaning breast cancer that has spread to other parts of the body.^[1] The trial data also show that the study is not limited to one breast cancer type, because it includes TNBC, HR+ BC, and HER2-positive or HER2-low disease.^[1]

These subtypes matter because breast cancer is not one single disease. Different subtypes can behave differently and may respond differently to treatment combinations.^[1]

What treatment combinations are being studied

The trial is looking at multiple treatment combinations, not just one treatment plan.^[1] The source lists several drugs used in different combinations, including RO7881583, empagliflozin, fulvestrant, sacituzumab govitecan, Verzenios, palbociclib, inavolisib, Tecentriq, letrozole, RoActemra, Kisqali, Abraxane, ACTEMRA, and metformin.^[1]

Some of these drugs are given by mouth, while others are given as an injection or infusion.^[1] The trial data do not explain the exact combination for each participant in the source provided, but they show that the study is testing several regimens within the same research program.^[1]

What the researchers are measuring

The main early efficacy measure in Stage 1 is objective response rate (ORR), which means the percentage of patients whose cancer shrinks or disappears during treatment.^[1] This helps researchers see whether a treatment combination shows signs of working.^[1]

Safety is also a major focus. The study measures the incidence, nature, and severity of adverse events, as well as laboratory abnormalities, and grades severity using NCI CTCAE v4.0.^[1] In simple terms, this means the study tracks side effects, how serious they are, and whether blood or other test results change in a concerning way.^[1]

The trial also measures changes from baseline in vital signs, ECG parameters, and targeted clinical laboratory test results in Stage 1 and Stage 2.^[1] Baseline means the measurements taken before treatment starts.^[1]

Trial phase and study design

This is a Phase 1 trial.^[1] Phase 1 studies are early research studies that mainly check safety and look for early signs of benefit.^[1]

The study is interventional, which means the researchers assign treatments rather than only observing what happens in routine care.^[1] The brief summary says Stage 1 is used to evaluate both efficacy and safety of the treatment combinations.^[1]

Key patient-focused points

• The trial is about ATIRMOCICLIB research in metastatic breast cancer, not a general drug review.^[1]

• The study includes several breast cancer subtypes, so it is trying to learn how treatment combinations work across different patient groups.^[1]

• The main questions are whether the treatment combinations help shrink cancer and whether they can be given safely.^[1]

• Researchers are also watching heart tracing results, blood tests, and vital signs to look for treatment-related changes.^[1]

• The planned enrollment of 325 participants suggests a fairly large early-stage trial program for this disease setting.^[1]

Table of contents

• Trial overview
• Who the trial is for
• What is being studied
• Trial phase and design
• Outcomes being measured
• Treatments in the study
• Patient-focused summary

Trial overview

The available clinical trial is an interventional study called the PREDICT clinical trial, and it is authorised.^[1] It studies depressive disorder and looks at whether a pre-emptive pharmacogenetic strategy can improve the choice of antidepressant treatment after a previous treatment has failed.^[1]

The trial includes 240 participants and is in Phase 3.^[1] Its brief summary says the study compares a personalized medicine approach with standard clinical practice in people who are starting a new therapy after treatment failure.^[1]

Who the trial is for

This trial is for patients with depressive disorder who need a new antidepressant after their prior therapy did not work well enough.^[1] The source data does not give more detailed entry rules such as age limits or exact lab requirements.^[1]

• Target population: people with depressive disorder.^[1]

• Treatment situation: starting a new antidepressant after prior treatment failure.^[1]

• Study setting: patients are being evaluated in a real treatment decision context, not just for one fixed drug choice.^[1]

What is being studied

The main question is whether a pre-emptive pharmacogenetic strategy can help choose antidepressants better than usual care.^[1] Pre-emptive means the testing is done before the treatment decision is made, and pharmacogenetic means the study uses gene-related information to guide medicine selection.^[1]

The study also uses demographic, clinical, and concomitant medication data when making treatment decisions.^[1] Concomitant medication means other medicines a patient is already taking at the same time.^[1]

Although the trial is about treatment selection rather than one single drug, TRIMIPRAMINE MALEATE is included among the treatment options listed in the study data.^[1]

Trial phase and design

This is a Phase 3 clinical trial.^[1] Phase 3 trials usually test how well a strategy works in a larger group and help compare it with routine care.^[1]

The study is interventional, which means researchers actively assign or guide the treatment approach being tested.^[1] In this case, the intervention is the personalized selection strategy, not only a single medicine.^[1]

Outcomes being measured

The main outcome is symptom remission, meaning the depression symptoms improve a lot or may no longer be present.^[1] The trial measures this by looking at changes in depression severity scores after the new antidepressant treatment begins.^[1]

• PHQ-9: a patient questionnaire used to measure depression severity.^[1]

• MADRS: a clinician-rated scale used to measure how severe depression symptoms are.^[1]

The outcome is assessed after initiation of the new antidepressant treatment following failure of the prior therapy at study entry.^[1]

Treatments in the study

The intervention list includes many antidepressants and related medicines, such as escitalopram, duloxetine, fluvoxamine, sertraline, desvenlafaxine, fluoxetine, vortioxetine, venlafaxine, amitriptyline hydrochloride, citalopram, bupropion, mirtazapine, valproxan, quetiapine, and TRIMIPRAMINE MALEATE.^[1]

These medicines are part of the treatment selection process being compared in the trial, so the study is focused on choosing the right antidepressant strategy rather than testing only one product by itself.^[1]

• Antidepressant choices: the trial includes several medicines so researchers can compare how well the selection strategy works in practice.^[1]

• Personalized selection: the study uses gene-related and clinical information to help decide which treatment may work best.^[1]

Patient-focused summary

For patients, this trial is about finding a better way to choose antidepressant treatment after one treatment has not helped enough.^[1] The study asks whether adding genetic testing and other patient information can improve the chance of remission compared with usual care.^[1]

The source data does not report results yet, so the main focus is on the study goal, the patient group, and the outcomes being measured.^[1]

Table of Contents

• Trial overview
• Who participated
• What was measured
• Study design and phase
• Condition focus: Crohn’s disease

Trial overview

This article covers one clinical trial of VERCIRNON, identified as 2022-502843-36-00, which was a completed Phase 1 interventional study.^[1] The study used a PET scan approach to examine where the radiotracer [11C]AZ14132516 goes in the body after VERCIRNON was given.^[1]

Who participated

The trial enrolled 9 healthy participants.^[1] Even though the participants were healthy, the study was linked to Crohn’s disease research because the condition was listed in the trial data.^[1]

What was measured

The main results were standard uptake value (SUV) and standard uptake value ratio (SUVR) in regions of interest.^[1] These scan measures help show how much tracer is taken up and how much total binding occurs to CCR9 in the body areas being studied.^[1]

The brief summary says the study aimed to examine the distribution of [11C]AZ14132516 and its binding to CCR9 in anatomical regions of interest in the abdominal area.^[1] In simple words, researchers wanted to see where the tracer traveled and how it behaved in the belly area on the scan.^[1]

Study design and phase

This was an interventional study, which means researchers gave the study intervention and then observed the results.^[1] It was in Phase 1, the earliest stage of clinical research, which is often used to gather first information about how a study test performs in people.^[1]

Condition focus: Crohn’s disease

The only condition named in the source data was Crohn’s disease.^[1] The trial did not describe treatment of symptoms; instead, it focused on imaging and binding measurements that may help researchers study this condition in the abdominal area.^[1]

Table of Contents

• Trial overview
• Pain study in neuropathic pain
• Epilepsy study in healthy adults
• What the studies measured
• Who took part
• Study design and phase

Trial overview

Two completed interventional studies investigated TRV045 in early human research.^[1][2] Both trials were Phase 1 studies with 24 participants each.^[1][2]

These studies focused on different conditions: one on pain linked to diabetic peripheral neuropathy, and one on epilepsy.^[1][2] The trial records show that both studies are completed.^[1][2]

Pain study in neuropathic pain

The first study was titled as a study of the pain-relieving effects of a new drug in healthy adults, and it focused on acute and chronic neuropathic pain secondary to diabetic peripheral neuropathy.^[1] Its brief summary says the goal was to evaluate the analgesic, or pain-relieving, effects of TRV045 using PainCart, including the UVB burn inflammatory model.^[1]

This study included TRV045 300 mg taken by mouth and a TRV045 placebo for comparison.^[1] The main outcome was pharmacodynamic measurements with the UVB pain model, which means the researchers wanted to see how the study drug changed pain-related responses in the body.^[1]

Epilepsy study in healthy adults

The second study looked at the safety, tolerability, absorption, excretion, and effects of a new drug for the treatment of epilepsy.^[2] Its brief summary says the study evaluated how TRV045 affects the ability of brain cells to conduct electrical stimulation, also called cortical excitability, in healthy male adults.^[2]

This study compared TRV045 250 mg taken by mouth with a placebo.^[2] The main outcome was the change from baseline in motor evoked potential, measured as peak-to-peak amplitude in microvolts, which is a way to test how the nervous system responds to stimulation.^[2]

What the studies measured

The pain study used pharmacodynamic measurements, which are tests that show how a treatment affects the body, especially in relation to pain.^[1] The UVB pain model and PainCart were used to look at pain responses in a controlled research setting.^[1]

The epilepsy study measured motor evoked potential, which is a signal recorded after stimulation to show how well the brain and nerves can pass electrical messages.^[2] The specific endpoint was the change from baseline in peak-to-peak amplitude, meaning the study compared the result after treatment with the starting value.^[2]

Who took part

One study involved healthy adults and the other specifically mentioned healthy male adults.^[1][2] The pain study also targeted people with conditions related to diabetic peripheral neuropathy, while the epilepsy study focused on epilepsy as the condition of interest.^[1][2]

Because both studies were Phase 1, they were early studies with small enrollment numbers rather than large treatment trials.^[1][2] This kind of research is usually used to learn basic information before larger studies are done.^[1][2]

Study design and phase

Both trials were interventional, meaning the researchers gave a study treatment and compared it with placebo.^[1][2] Each study was completed and had 24 participants, which shows they were small early-stage trials.^[1][2]

The records do not show later-phase testing here, so the available information is limited to these early Phase 1 studies.^[1][2]

Table of Contents

• Trial overview
• Who is being studied
• Study design and treatment groups
• What is being measured
• Trial status and size

Trial overview

The listed study of SONLICROMANOL HYDROCHLORIDE is a randomized, double-blind, placebo-controlled Phase 2 trial in people with long COVID.^[1] It is an interventional study, which means the researchers assign a treatment and then measure the results.^[1]

The trial is authorised and plans to enroll 80 participants.^[1] Its brief summary says the study is looking at reduction of post-COVID related fatigue measured with the FAS at week 13.^[1]

Who is being studied

The target condition is long COVID, also called post-COVID symptoms in the study summary.^[1] The main symptom being studied is fatigue, which means ongoing tiredness or low energy.^[1]

This means the trial is focused on people whose symptoms continue after a COVID-19 infection, especially those affected by persistent fatigue.^[1]

Study design and treatment groups

The trial is randomized, so participants are assigned to study groups by chance.^[1] It is also double-blind, which means neither the participants nor the study team know who receives the active treatment or the placebo during the study.^[1]

The comparison is between SONLICROMANOL HYDROCHLORIDE and placebo, an inactive look-alike treatment used to help show whether the study drug has a real effect.^[1] The intervention list includes Sonlicromanol tablets and a placebo, and also lists Sonlicromanol 180 mg by buccal use.^[1]

What is being measured

The primary outcome is fatigue symptoms measured at week 13 by the FAS.^[1] A primary outcome is the main result the researchers want to study.^[1]

The FAS is a fatigue assessment scale, which is a tool used to measure how severe tiredness is.^[1] In simple terms, the study wants to see whether SONLICROMANOL HYDROCHLORIDE can improve fatigue more than placebo after 13 weeks.^[1]

Trial status and size

The study status is Authorised, which means it has approval to proceed.^[1] With 80 planned participants, this is a small Phase 2 study designed to give an early answer about possible benefit in long COVID fatigue.^[1]

Because the trial is still in Phase 2, the main goal is to learn more about whether the treatment may help and to continue evaluating it in a limited group of patients.^[1]